Compare Stocks: PRME, BEAM, CRSP, and BCRX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$9.06 -9.0%	$9.74	$6.00 ▼ $11.22	$2.55B	0.57	2.67 million shs	9.69 million shs
BEAM Beam Therapeutics	$26.83 -9.5%	$29.09	$19.35 ▼ $38.26	$3.06B	2.22	1.51 million shs	6.17 million shs
CRSP CRISPR Therapeutics	$54.78 -1.8%	$53.86	$44.12 ▼ $78.48	$5.39B	1.76	1.37 million shs	1.39 million shs
PRME Prime Medicine	$3.56 -3.8%	$3.40	$2.67 ▼ $6.94	$671.09M	2.34	2.36 million shs	3.60 million shs

7 Stocks That Could Lead the Next Market Boom

Tesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	+2.68%	+6.18%	+19.57%	+20.44%
BEAM Beam Therapeutics	0.00%	+0.78%	+7.93%	-2.66%	+42.05%
CRSP CRISPR Therapeutics	0.00%	-2.09%	+4.24%	+8.37%	+1.70%
PRME Prime Medicine	0.00%	+3.06%	+20.13%	+28.47%	-0.54%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
BCRX BioCryst Pharmaceuticals	$9.06 -9.0%	$9.74	$6.00 ▼ $11.22	$2.55B	0.57	2.67 million shs	9.69 million shs
BEAM Beam Therapeutics	$26.83 -9.5%	$29.09	$19.35 ▼ $38.26	$3.06B	2.22	1.51 million shs	6.17 million shs
CRSP CRISPR Therapeutics	$54.78 -1.8%	$53.86	$44.12 ▼ $78.48	$5.39B	1.76	1.37 million shs	1.39 million shs
PRME Prime Medicine	$3.56 -3.8%	$3.40	$2.67 ▼ $6.94	$671.09M	2.34	2.36 million shs	3.60 million shs

7 Stocks That Could Lead the Next Market Boom

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
BCRX BioCryst Pharmaceuticals	0.00%	+2.68%	+6.18%	+19.57%	+20.44%
BEAM Beam Therapeutics	0.00%	+0.78%	+7.93%	-2.66%	+42.05%
CRSP CRISPR Therapeutics	0.00%	-2.09%	+4.24%	+8.37%	+1.70%
PRME Prime Medicine	0.00%	+3.06%	+20.13%	+28.47%	-0.54%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
BCRX BioCryst Pharmaceuticals	2.67	Moderate Buy	$20.60	127.37% Upside
BEAM Beam Therapeutics	2.69	Moderate Buy	$49.00	82.63% Upside
CRSP CRISPR Therapeutics	2.61	Moderate Buy	$68.06	24.23% Upside
PRME Prime Medicine	2.89	Moderate Buy	$7.47	109.89% Upside

Current Analyst Ratings Breakdown

Latest PRME, BEAM, CRSP, and BCRX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/8/2026	BCRX BioCryst Pharmaceuticals	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$16.00
8/31/2026	PRME Prime Medicine	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (E+)
8/31/2026	CRSP CRISPR Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/31/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00
8/31/2026	CRSP CRISPR Therapeutics	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$82.00
8/27/2026	BCRX BioCryst Pharmaceuticals	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Hold (C)
8/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00
8/25/2026	CRSP CRISPR Therapeutics	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform
8/25/2026	BEAM Beam Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$80.00
8/25/2026	CRSP CRISPR Therapeutics	Citizens Jmp Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Market Outperform	$80.00
8/25/2026	PRME Prime Medicine	Chardan Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$7.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
BCRX BioCryst Pharmaceuticals	$874.84M	2.65	$1.13 per share	8.04	($0.57) per share	-15.89
BEAM Beam Therapeutics	$156.04M	17.76	N/A	N/A	$12.20 per share	2.20
CRSP CRISPR Therapeutics	$11M	481.53	N/A	N/A	$20.17 per share	2.72
PRME Prime Medicine	$4.63M	139.46	N/A	N/A	$0.67 per share	5.31

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
BCRX BioCryst Pharmaceuticals	$263.86M	-$1.50	N/A	12.58	N/A	-40.90%	-86.89%	66.37%	11/2/2026 (Estimated)
BEAM Beam Therapeutics	-$79.99M	-$0.86	N/A	N/A	N/A	-54.75%	-30.71%	-24.07%	11/3/2026 (Estimated)
CRSP CRISPR Therapeutics	-$581.60M	-$4.76	N/A	N/A	N/A	-3,368.72%	-24.39%	-18.25%	11/9/2026 (Estimated)
PRME Prime Medicine	-$201.14M	-$1.06	N/A	N/A	N/A	-4,613.11%	-188.27%	-59.11%	N/A

Latest PRME, BEAM, CRSP, and BCRX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/6/2026	Q2 2026	PRME Prime Medicine	-$0.24	-$0.24	N/A	-$0.24	$4.40 million	$1.15 million
8/5/2026	Q2 2026	BCRX BioCryst Pharmaceuticals	$0.1542	$0.30	+$0.1458	$0.30	$183.28 million	$218.25 million
8/4/2026	Q2 2026	BEAM Beam Therapeutics	-$1.11	-$1.18	-$0.07	-$1.18	$16.37 million	$0.49 million
8/3/2026	Q2 2026	CRSP CRISPR Therapeutics	-$1.19	-$0.94	+$0.25	-$0.94	$7.45 million	$10.18 million
6/30/2026	Q2 2026	CRSP CRISPR Therapeutics	N/A	-$0.94	N/A	-$0.94	N/A	$10.18 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
BCRX BioCryst Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
BEAM Beam Therapeutics	$0.90	3.35%	N/A	N/A	N/A
CRSP CRISPR Therapeutics	N/A	N/A	N/A	N/A	N/A
PRME Prime Medicine	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
BCRX BioCryst Pharmaceuticals	N/A	2.32	2.29
BEAM Beam Therapeutics	0.09	14.57	14.57
CRSP CRISPR Therapeutics	0.34	17.85	17.85
PRME Prime Medicine	N/A	3.05	3.05

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
BCRX BioCryst Pharmaceuticals	85.88%
BEAM Beam Therapeutics	99.68%
CRSP CRISPR Therapeutics	69.20%
PRME Prime Medicine	70.37%

Insider Ownership

Company	Insider Ownership
BCRX BioCryst Pharmaceuticals	3.80%
BEAM Beam Therapeutics	3.80%
CRSP CRISPR Therapeutics	5.20%
PRME Prime Medicine	16.04%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
BCRX BioCryst Pharmaceuticals	530	255.54 million	245.83 million	Optionable
BEAM Beam Therapeutics	510	103.29 million	99.36 million	Optionable
CRSP CRISPR Therapeutics	460	96.69 million	91.67 million	Optionable
PRME Prime Medicine	N/A	181.38 million	152.28 million	N/A

PRME, BEAM, CRSP, and BCRX Headlines

Recent News About These Companies

Prime Medicine to Participate in Upcoming Investor Conferences

September 3, 2026 | globenewswire.com

BlackRock Inc. Acquires Shares of 9,602,041 Prime Medicine, Inc. $PRME

September 2, 2026 | marketbeat.com

Prime Medicine, Inc. (NASDAQ:PRME) Given Average Recommendation of "Moderate Buy" by Brokerages

August 28, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Upgraded to Strong-Buy at Chardan Capital

August 27, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Stock Price Down 4.7% - What's Next?

August 26, 2026 | marketbeat.com

ADAR1 Capital Management LLC Makes New Investment in Prime Medicine, Inc. $PRME

August 26, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Shares Up 6.3% - Here's What Happened

August 25, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Trading Down 6.9% - Should You Sell?

August 20, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Rating Increased to Strong-Buy at BMO Capital Markets

August 20, 2026 | marketbeat.com

Prime Medicine (NASDAQ:PRME) Shares Gap Up - Still a Buy?

August 19, 2026 | marketbeat.com

Alphabet Inc. Takes Position in Prime Medicine, Inc. $PRME

August 18, 2026 | marketbeat.com

Prime Medicine: Soon In The Clinic

August 15, 2026 | seekingalpha.com

Q3 EPS Estimates for Prime Medicine Boosted by HC Wainwright

August 12, 2026 | marketbeat.com

Prime Medicine: An Initial Prognosis

August 11, 2026 | seekingalpha.com

Prime Medicine Advances First-in-Human Prime Editing Trial in Wilson Disease

August 11, 2026 | tipranks.com

Prime Medicine (NASDAQ:PRME) Trading Up 7.3% - Still a Buy?

August 10, 2026 | marketbeat.com

Prime Medicine's (PRME) "Buy" Rating Reaffirmed at HC Wainwright

August 10, 2026 | marketbeat.com

Renaissance Technologies LLC Sells 408,120 Shares of Prime Medicine, Inc. $PRME

August 10, 2026 | marketbeat.com

Prime Medicine, Inc. (PRME) Reports Q2 Loss, Misses Revenue Estimates

August 6, 2026 | zacks.com

Prime Medicine Reports Second Quarter 2026 Financial Results and Provides Business Updates

August 6, 2026 | finance.yahoo.com

Prime Medicine, Inc. (PRME) May Report Negative Earnings: Know the Trend Ahead of Q2 Release

July 30, 2026 | zacks.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, BEAM, CRSP, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

$9.06 -0.90 (-9.04%)

Closing price 04:00 PM Eastern

Extended Trading

$9.14 +0.08 (+0.88%)

As of 07:59 PM Eastern

BioCryst Pharmaceuticals, Inc., a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema. It is also developing BCX10013, an oral factor D inhibitor for complement-mediated diseases. The company has collaborations and in-license relationships with the Torii Pharmaceutical Co., Ltd.; Seqirus UK Limited; Shionogi & Co., Ltd.; Green Cross Corporation; National Institute of Allergy and Infectious Diseases; Biomedical Advanced Research and Development Authority; the U.S. Department of Health and Human Services; and The University of Alabama at Birmingham, as well as Albert Einstein College of Medicine of Yeshiva University and Industrial Research, Ltd. BioCryst Pharmaceuticals, Inc. was founded in 1986 and is headquartered in Durham, North Carolina.

Beam Therapeutics NASDAQ:BEAM

$26.83 -2.83 (-9.54%)

Closing price 04:00 PM Eastern

Extended Trading

$26.91 +0.08 (+0.30%)

As of 07:59 PM Eastern

Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. It develops BEAM-101 for the treatment of sickle cell disease or beta-thalassemia; and BEAM-302, a liver-targeting LNP formulation to treat severe alpha-1 antitrypsin deficiency; BEAM-201, an anti-CD7 CAR-T product candidate, which is in Phase 1/2 clinical trials for the treatment of refractory T-cell acute lymphoblastic leukemia/T cell lymphoblastic lymphoma; and BEAM-301, a liver-targeting LNP formulation for the treatment of glycogen storage disease 1a. The company has research collaboration agreement with Pfizer Inc., focus on in vivo base editing programs for targets rare genetic diseases of the liver, muscle, and central nervous system; Apellis Pharmaceuticals to conduct preclinical research on target specific genes within the complement system in various organs, including the eye, liver, and brain; Verve Therapeutics, Inc., for cardiovascular disease treatments; Sana Biotechnology, Inc., to research, develop, and commercialize rights to CRISPR Cas12b for cell therapy programs; and Orbital Therapeutics design RNA for the prevention, treatment or diagnosis of human disease. Beam Therapeutics Inc. was incorporated in 2017 and is based in Cambridge, Massachusetts.

CRISPR Therapeutics NASDAQ:CRSP

$54.78 -1.01 (-1.81%)

Closing price 04:00 PM Eastern

Extended Trading

$54.30 -0.48 (-0.87%)

As of 07:57 PM Eastern

CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.

Prime Medicine NASDAQ:PRME

$3.56 -0.14 (-3.78%)

Closing price 04:00 PM Eastern

Extended Trading

$3.56 +0.00 (+0.08%)

As of 07:56 PM Eastern

We are a biotechnology company committed to delivering a new class of differentiated one-time curative genetic therapies, Prime Editors, to address the widest spectrum of diseases by deploying our Prime Editing technology, which we believe is a versatile, precise, efficient and broad gene editing technology. Genetic mutations implicated in disease are diverse and can range from errors of a single base, known as point mutations, to errors that extend beyond a single base, such as insertions, deletions, duplications, or combinations thereof. We believe the ability to alter the human genome at the foundational level may confer the greatest therapeutic impact on human disease. Gene editing, including platforms such as Prime Editing, is a novel technology that is not yet clinically validated for human therapeutic use. Over the last decade, the field of genetic medicine has evolved tremendously, with groundbreaking advances in gene therapy, cell therapy, RNA therapy, and, more recently, gene editing. These technologies represent dramatic advancements for genetic therapies, but lack the versatility to precisely and efficiently correct the diverse range of mutations or DNA alterations implicated in disease. Prime Medicine was co-founded by a world-renowned leader in the field of gene editing, David Liu, Ph.D. Dr. Liu was joined as co-founder by Andrew Anzalone, M.D., Ph.D., who conceived of and developed Prime Editing technology. Drawn by the promise of Prime Editing’s ability to transform the field of gene editing, we have assembled a diverse team that has grown to more than 150 people as of September 30, 2022. There are no current plans for Dr. Liu to be an officer or director of our company following this offering. He is expected to continue to provide consulting services to us pursuant to a consulting agreement, which has a current term that runs through September 2025 and accommodates a previous commitment with respect to Beam Therapeutics Inc., which could result in or may create the appearance of a conflict of interest. He is also expected to retain his position and affiliation with the Broad Institute, Inc., Howard Hughes Medical Institute and Harvard University. On September 20, 2022, we achieved a major milestone as the United States Patent and Trademark Office, or the USPTO, issued U.S. Patent 11,447,770, or the ‘770 Patent, covering methods of using Prime Editors. The Broad Institute, Inc., or Broad Institute, prepared, filed and prosecuted the ‘770 Patent. While Broad Institute is the owner of the ‘770 Patent, it is exclusively licensed to us under the terms of the license agreement with Broad Institute. The ‘770 Patent is the first issued Prime Editing patent in our licensed patent portfolio and we believe it will be instrumental in protecting our Prime Editing platform and pipeline of gene editing programs. We believe our in-licensed and company-owned Prime Editing technology has transformative potential that could change the course of how disease is treated and overcome the challenges associated with current genetic therapies. We in-license our Prime Editing technology pursuant to a license agreement with Broad Institute. In addition, the license agreement grants us certain rights and licenses under certain patent rights Broad Institute owns or controls, including a license to the ‘770 Patent, which covers Prime Editing technology and expires in 2040. The licenses are limited to the field of prevention or treatment of human disease, and most licenses granted to us under the license agreement are further limited to the prevention or treatment of human disease by editing (including modifying or converting) or targeting DNA ex vivo, in vivo, or through xeno transplantation methods, which we refer to as the Prime Broad Field. We were incorporated under the laws of the State of Delaware in September 2019 under the name Prime Medicine, Inc. Our principal executive offices are located at 21 Erie Street, Cambridge, MA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRME, BEAM, CRSP, and BCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRME, BEAM, CRSP, and BCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRME, BEAM, CRSP, and BCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, BEAM, CRSP, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

Beam Therapeutics NASDAQ:BEAM

CRISPR Therapeutics NASDAQ:CRSP

Prime Medicine NASDAQ:PRME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PRME, BEAM, CRSP, and BCRX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PRME, BEAM, CRSP, and BCRX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PRME, BEAM, CRSP, and BCRX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PRME, BEAM, CRSP, and BCRX Company Descriptions

BioCryst Pharmaceuticals NASDAQ:BCRX

Beam Therapeutics NASDAQ:BEAM

CRISPR Therapeutics NASDAQ:CRSP

Prime Medicine NASDAQ:PRME

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools